
Article 1 
The substance L-cysteine is approved as a basic substance as laid down in Annex I.
Article 2 
Implementing Regulation (EU) No 540/2011 is amended in accordance with Annex II to this Regulation.
Article 3 
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
This Regulation shall be binding in its entirety and directly applicable in all Member States.Done at Brussels, 12 May 2020.
For the Commission
The President
Ursula VON DER LEYEN
ANNEX I

Common Name, Identification Numbers IUPAC Name Purity Date of approval Specific provisions
L-cysteine (E 920)CAS No: 52-89-1EINECS: 200-157-7(L-cysteine hydrochloride)CAS No: 7048-04-6EINECS: 615-117-8(L-cysteine hydrochloride monohydrate) L-cysteine hydrochloride (1:1) Min. 98,0 % L-cysteine hydrochloride (on anhydrous basis)Food grade in conformity with Commission Regulation (EU) No 231/2012.max. 1,5 mg/kg Asmax. 5 mg/kg Pb 2.6.2020 L-cysteine (E 920) shall be used as a mixture with matrix (flour, food grade) at a concentration of maximum 8% (of L-cysteine hydrochloride, on anhydrous basis) in accordance with the specific conditions included in the conclusions of the review report on L-cysteine (SANTE/11056/2019) and in particular Appendices I and II thereto.


ANNEX II

In Part C of the Annex to Implementing Regulation (EU) No 540/2011, the following entry is added:

Number Common Name, Identification Numbers IUPAC Name Purity Date of approval Specific provisions
‘21 L-cysteine (E 920)CAS No: 52-89-1EINECS: 200-157-7(L-cysteine hydrochloride)CAS No: 7048-04-6EINECS: 615-117-8(L-cysteine hydrochloride monohydrate) L-cysteine hydrochloride (1:1) Min. 98,0 % L-cysteine hydrochloride (on anhydrous basis)Food grade in conformity with Commission Regulation (EU) No 231/2012.max. 1,5 mg/kg Asmax. 5 mg/kg Pb 2.6.2020 L-cysteine (E 920) shall be used as a mixture with matrix (flour, food grade) at a concentration of maximum 8% (of L-cysteine hydrochloride, on anhydrous basis) in accordance with the specific conditions included in the conclusions of the review report on L-cysteine (SANTE/11056/2019) and in particular Appendices I and II thereto.’

